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Objectives: To describe the clinical features of patients presenting with ‘‘idiopathic’’ intersti-
tial pneumonia that were diagnosed with anti-synthetase syndrome based on clinical features
and positive anti-PL-7 or PL-12 antibodies.
Methods: Over a 24-month period, we evaluated 37 patients who presented with clinical
features of anti-synthetase (AS) syndrome, negative anti-Jo-1 antibodies, and who were as-
sessed for other anti-tRNA synthetase (anti-tRS) antibodies. All data were abstracted from
the medical record.
Results: Nine (24%) were confirmed to have non-anti-Jo-1 positive AS syndrome based on clinical
features and the presence of other anti-tRS antibodies (seven with anti-PL-7, two with anti-PL-
12 antibodies). All presented with dyspnea as the initial symptom and with ILD as the first mani-
festation. Elevated CPK was identified in three patients but only two had muscle weakness.
Pulmonary physiology revealed restriction (forced vital capacity 60% of predicted) and impaired
gas transfer (diffusing capacity for carbon monoxide 40% of predicted). All had similar findings on
thoracic HRCT scans, with basilar predominance of abnormalities and patterns suggestive of non-
specific interstitial pneumonia and organizing pneumonia. Immunomodulatory therapies were
used to treat the ILDdresponses were variable, but some subjects clearly improved.body; AS, anti-synthetase syndrome; DM, dermatomyositis; HRCT, high-resolution computed tomo-
PM, polymyositis; RP, Raynaud’s phenomenon.
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1720 A. Fischer et al.Conclusion: Anti-PL-7 and PL-12 antibodies may be more common among patients presenting
with ‘‘idiopathic’’ interstitial pneumonia than formerly considered and should be checked in
patients with features of AS syndrome despite a negative screen for anti-nuclear or anti-Jo-1
antibodies. Further research is needed to advance understanding of anti-PL-7 or anti-PL-12-posi-
tive AS syndrome, including its prognosis and optimal approaches to therapy.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The interstitial lung diseases (ILD) comprise a diverse group
of disorders characterized histologically by varying degrees
of inflammation and fibrosis.1,2 Two major categories of
causes for ILD include exposures (e.g., aerosolized organic
antigens, dusts, drugs) and connective tissue disease (CTD).
Many ILDs, including the idiopathic interstitial pneumonias
(IIP), have no identifiable etiology. The IIP comprise a group
of conditions with similar clinical, radiologic, and physio-
logic findings, but different histologic patterns in surgical
lung biopsy specimens.1 These histologic patterns are not
specific to the IIP and may be seen, for example, in ILD
related to underlying CTD. Recent data suggest that, for
a given histologic pattern, CTD-related ILD has a more
favorable prognosis than IIP, thus arguing for the careful
evaluation of patients labeled with idiopathic ILD in an
attempt to identify underlying CTD.3,4
Recognition of CTD is particularly challenging when ILD
is its first or lone manifestation or when extra-thoracic
features of CTD are subtle.5e7 Attempts to identify under-
lying CTD most often include a thorough history, physical
examination, and serologic assessment for the presence of
autoantibodies (e.g., anti-nuclear antibodies [ANA] and
rheumatoid factor [RF]). It is unclear whether these
attempts are sufficient or whether additional testing is
useful or necessary to identify the presence of CTD.
The association between ILD and the myositis spectrum of
CTD is well-known.8,9 Patients with myositis (either poly-
myositis [PM] or dermatomyositis [DM]) are considered to
have the anti-synthetase (AS) syndrome when they are found
to have an anti-tRNA synthetase (anti-tRS) autoantibody and
one or more of these clinical features in decreasing order of
frequency; myositis, ILD, arthritis or arthralgias, Raynaud’s
phenomenon (RP), ‘‘mechanic’s hands’’ (fissured, rough-
ened skin over the tips and thenar side of the fingers), and
fever.10 Esophageal dysmotility is a well-known manifesta-
tion of CTD, in general; and it is often seen with myositis or
the AS syndrome, in particular.
The anti-tRS autoantibodies target aminoacyl-transfer
RNA synthetases that catalyze the binding of specific amino
acids to their cognate tRNA during protein synthesis. The
most commonly identified and readily commercially tested
anti-tRS antibody is anti-Jo-1 (anti-histidyl-tRNA synthe-
tase).11 Others include anti-PL-7 (anti-threonyl), anti-PL-12
(anti-alanyl), anti-OJ (anti-isoleucyl), anti-EJ (anti-glycyl),
anti-KS (anti-asparaginyl), anti-ZO (anti-phenylalanyl), and
an anti-tyrosyl tRS antibody.12 Anti-Jo-1 is found in about
30%, anti-PL-7 or anti-PL-12 in 3e4%, and the other anti-tRS
antibodies in <2% of patients with myositis.13 Numerous
studies have elucidated the link between anti-Jo-1antibodies and ILD14,15; however, there are few data on the
characteristics of myositis patients with other anti-tRS
antibodies.
We conducted this study in an attempt to achieve three
specific goals: first, to add to the limited literature of and
raise awareness for what we believe to be an under-
recognized cause of fibrotic ILDdnon-anti-Jo-1 AS syndrome.
Second, we aimed to highlight the chest HRCT findings of
ILD associated with the AS syndrome. Finally, we wished
to emphasize the challenges physicians face in treating
ILD in the AS syndrome. The objective of this study was
to describe the clinical features of a series of patients
who presented with ‘‘idiopathic’’ interstitial pneumonia
but were diagnosed with AS syndrome based on clinical
features and positive anti-PL-7 or anti-PL-12 antibodies.
Methods
Over a 24-month period, we identified 37 patients evaluated
at our center for ‘‘idiopathic’’ interstitial pneumonia who had
clinical features suggestive of AS syndrome, negative anti-Jo-
1 antibodies, and were assessed for other anti-tRS antibodies.
We abstracted from medical records data on demographics,
clinical presentation, pulmonary physiology, chest radiology,
histology, and therapy. No patient presented with a disease or
exposure linked with ILD. As part of their comprehensive ILD
evaluation, all patients underwent standardized compre-
hensive clinical testing that included serologic testing,
thoracic high-resolution computed tomography (HRCT),
barium contrast esophagography, and pulmonary function
testing. Most patients were seen by both ILD and rheuma-
tology specialists. The decision to test for anti-tRS antibodies
other than anti-Jo-1 was a clinical one made by the consulting
physicians. This testing was conducted by ordering the
‘‘Myositis Antibody Panel’’ through Oklahoma Medical
Research Foundation (OMRF) Clinical Immunology Laboratory
in Oklahoma City, OK. This was a HIPAA-compliant protocol,
approved by our institutional review board. Data are pre-
sented as counts or medians with interquartile ranges.
Results
All patients presented with ILD of unknown etiology and
were anti-Jo-1 antibody negative. Nine (24%) of thirty-
seven patients were confirmed to have AS syndrome based
on clinical features and confirmatory anti-tRS antibody
positivity. Seven had anti-PL-7 antibodies and two had anti-
PL-12 antibodies. No other anti-tRS antibody was identified.
Clinical characteristics of these nine patients are presented
in Table 1. Six patients had esophageal dysmotility, four
Table 1 Baseline characteristics of study subjects.
Subjects NZ 9
Age in years 60.1 (41.1e67.3)
Female:male 5:4
Ever cigarette smoker 4
Ethnicity
PL-7 White 5
Asian 1
Latino 1
PL-12 White 1
Latino 1
Clinical features
Dyspnea 9
Raynaud’s phenomenon 4
Arthritis 4
Esophageal disease 6
Laboratory
Elevated CPK 3
Autoantibodies
ANA 0
SSA 2
PL-7 7
PL-12 2
Pulmonary physiology
FVC% 60 (50e65)
DLCO% 40 (37e46)
HRCT pattern
fNSIP 9
Surgical biopsy 5
mNSIPþOP 2
fNSIPþOP 1
fNSIP (upper)þ UIP (lower) 1
ALIþOP 1
Data are counts, median (interquartile range); CPKZ creatine
phosphokinase; ANAZ anti-nuclear; antibody; FVC%Z percent
predicted forced vital capacity; DLCO%Z percent predicted
diffusing capacity of the lung for carbon monoxide; mNSIPZ
mixed cellular and fibrotic non-specific interstitial pneumonia;
OPZ organizing pneumonia; fNSIPZ fibrotic NSIP; UIPZ usual
interstitial pneumonia; ALIZ acute lung injury.
Table 2 Response to therapy in each subject.
Subject Gender Synthetase Ab Muscle involvement Pre-Tx
1 M PL-7 Yes 2.71(50
2 M PL-7 Yes 3.22(74
3 M PL-7 No 3.5(65)/
4 F PL-7 No 2.47(76
5 M PL-7 Yes 2.99(63
6 F PL-7 No 1.6(61)/
7 F PL-7 No 1.65(58
8 F PL-12 No 1.66(45
9 F PL-12 No 0.9(23)/
PZ prednisone; CYCZ cyclophosphamide; MMFZmycophenolate mo
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nailfold capillaroscopy, four had inflammatory arthritis,
three had ‘‘mechanic’s hands’’, and two had Gottron’s
papules. Elevated CPK was identified in three patients
(median 75, range 22e925), but only two had muscle
weakness. The other twenty-eight patients were consid-
ered to have either an undifferentiated CTD or remained
unclassifiable/idiopathic and were not further analyzed.
Dyspnea was the initial symptom, and ILD was the pre-
senting manifestation, in all nine subjects. Dyspnea was
present for a median 17 months prior to the diagnosis of AS
syndrome. In the two patients with muscle weakness and
elevated CPK, dyspnea pre-dated muscle symptoms by two
and five months respectively. Over a median 12.6 months of
follow-up, none of the six subjects with normal CPK levels
at presentation developed CPK enzyme elevation.
Therapeutic choices and responses to them are pre-
sented for each subject in Table 2. All subjects with AS are
living. Representative slices from HRCT scans are displayed
in Fig. 1; they show the characteristic findings of AS-related
ILD, including extreme basilar ground glass and reticular
opacities, areas of consolidation, and traction bron-
chiectasisda constellation of findings that suggests a mixed
histologic pattern of non-specific interstitial pneumonia
(NSIP) and organizing pneumonia.
Discussion
Over the last 24 months, among thirty-seven patients
labeled with idiopathic ILD, we identified nine with anti-
PL-7 or anti-PL-12-positive AS syndrome. In each subject,
ILD was the initial manifestation that prompted clinical
evaluation. Most of the patients were evaluated by both
pulmonologists and rheumatologists as part of their
comprehensive ILD evaluation. In general, the response of
the ILD to potent immunomodulatory therapydglucocorti-
coids with or without a cytotoxic agentdwas variable.
To date, at least seven anti-tRS antibodies have been
identified; anti-Jo-1 is the most common, and it is the most
widely recognized myositis-specific antibody.16 Anti-tRS
antibodies appear to be specific for the AS syndrome; they
appear to be mutually exclusive (patients with AS syndrome
have only one AS antibody); and they do not cross-react
among aminoacyl-tRNA synthetase enzymesdthat is, each
enzyme is specific for only one amino acid.16 It remains toFVC(%)/DLCO(%) Rx Duration On Rx FVC(%)/DLCO(%)
)/15.6(40) P, CYC 6mos 3.23(60)/13.9(36)
)/10.32(37) P, MMF e e
30.1(78) None 10mos 3.73(70)/30.9(80)
)/10.5(39) MMF 21mos 2.55(74)/11.1 (43)
)/13/66 (40) P, MMF 16mos 3.38 (72)/14.5 (43)
13 (68) P, MMF 4mos 1.7(62)/13.5 (69)
)/10.4(46) None e e
)/10.1(35) P, AZA 6mos 1.4(38)/8.11(28)
unable P, CYC 2mos 1.0(25)/3.52(12)
fetil; AZAZ azathioprine.
Figure 1 HRCT findings in AS Syndrome. Patients AeC display coronal slices from three patients with AS syndrome. Note the
extreme basilar predominance of findings, the extensive traction bronchiectasis in Panel B and how the opacities in all three panels
hug or ‘‘pancake’’ the diaphragms. White arrows in Panel A and black arrows in Panel B point to the major fissures being pulled
caudally from the extensive lower lobe volume loss. Similar findings are seen in Panel C. Panels D and E are transverse slices from
the same patient as Panel C. The black arrow in Panel D points to the extreme caudal aspect of the middle lobe affected by
extensive ground glass opacitites and tranction bronchiectasis. Note the patulous esophagus . Similar findings in the lung paren-
chyma are seen in Panel E.
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and whether they are pathogenic (i.e. responsible for tissue
injury) in patients with AS syndrome. Some studies have
suggested viral infection might induce the production of
anti-tRS antibodies.17,18
Interstitial lung disease is a common manifestation of
the AS syndrome and strongly associated with the presence
of anti-tRS antibodies. Love and colleagues examined
a large National Institutes of Health myositis database and
noted the presence of ILD in nearly 90% of subjects with
anti-tRS antibodies.14 Among the 212 subjects in that study,
48 (23%) had anti-tRS antibodiesdmost had anti-Jo-1, five
had anti-EJ, four had anti-PL-7, two had anti-OJ, and one
had anti-PL-12 antibodies. Sixty-two percent of subjects
with anti-tRS antibodies were Caucasian, 23% were black,
54% met diagnostic criteria for DM, and 40% met criteria for
PM. Among the subgroup with anti-tRS antibodies, findings
at presentation included fever in 87%, RP in 62%, myalgias
in 84%, arthritis in 94%, ‘‘mechanic’s hands’’ in 71%, and
positive ANA in only 44%. The five-year survival rate for
subjects with anti-tRS antibodies was nearly 75%.
Targoff and Arnett reported clinical features of eight
patients with anti-PL-12 antibodies.16 Five were black, two
were white, and one was Latino. Seven were female; six
had elevated CPK; three had arthritis; and three had RP.
Significant ILD was identified in seven. In a study from
Japan, Yamasaki and colleagues identified 36 subjects who
were evaluated at their center from 1991 to 2002 and found
to have anti-tRS antibodiesdsix with anti-PL-7, eight with
anti-Jo-1, and two with anti-PL-12 antibodies.19 All six
subjects with anti-PL-7 and all eight subjects with anti-Jo-1
antibodies had ILD. Interestingly, La Corte and colleagues
studied twenty-one subjects with AS and found those withSS-A antibodies had more extensive ILD by HRCT.20 This was
not true in our subjects, but only two had SS-A antibodies.
Data on therapy for anti-PL-7 or anti-PL-12 associated ILD
are few, and systematic evaluations are lacking. Glucocor-
ticoids have been the mainstay of therapy. Immunomodu-
latory agents used in combination with glucocorticoids have
included azathioprine, calcineurin antagonists, and cyclo-
phosphamidedeffects on symptoms and pulmonary physi-
ology have been variable.21e24 In a few of our nine subjects,
potent anti-inflammatory/immunomodulatory therapy led
to physiological improvementdmirroring the variable
response to therapy reported in previously published
studies. As with ILD from other causes, in which the clinical
course is variable and inexorable progression is not neces-
sarily the rule, whether patients whose physiology remained
stable on therapy might have declined if untreated is
uncertain.
As in these prior series, the subjects in the current study
had various features of the AS syndrome; the one constant
finding was fibrotic ILD that was moderate to very severe in
the majority. It is noteworthy to highlight the unique HRCT
features in our cohort. The extreme basilar predominance
of findings, including reticular and ground glass opacities
and traction bronchiectasis with or without consolidation,
that hug or ‘‘pancake’’ the diaphragms, and the lower lobe
volume loss, with the major fissures being dragged caudally
are, in our experience, fairly specific for AS-related ILD.
Other investigators have examined HRCT scan findings in
patients with AS: the most common radiologic features in
a study of seventeen subjects with anti-Jo-1 antibodies and
ILD by Karadimitrakis and colleagues25 were ground glass
opacities (41%), reticular opacities (35%), and honey-
combing (35%). Although the authors commented that the
Anti-synthetase syndrome in ANA 1723ground glass opacities were lower zone predominant
and that the radiologic features suggested an underlying
histologic pattern of NSIP, they did not mention the dia-
phragmatic ‘‘hugging’’ we observed in our subjects.
When confronted with an ‘‘idiopathic’’ interstitial pneu-
monia, there is no standard approachdor uniform set of
serologies to obtaindto reliably exclude underlying CTD. ILD
may be the forme fruste presentation of CTD, and in our
experience, effective cross-specialty interactions among
rheumatologists and pulmonologists is needed to optimize
the evaluation of such patients. None of our subjects had
a positive ANA; thus, practitioners should not be dissuaded
from considering CTD (including the AS syndrome) as
a potential etiology for ILD simply because the ANA is
negative. In our cohort, subtle clinical features such as
detecting RP, ‘‘mechanic’s hands’’, and esophageal dysmo-
tility were relevant and aided in the overall clinical assess-
ment. Clinicians involved in the evaluation of patients with
ILD need to thoroughly probe for subtle extra-thoracic
features and have a low-threshold to involve rheumatologic
expertise in the evaluation process.5e7 The assessment for
anti-tRS antibodies allowed accurate CTD identification in
24% (9/37) of our patients. The other twenty-eight subjects
were considered to have either undifferentiated CTD based
on clinical features along with non-specific autoantibody
positivity (such as ANA and anti-SSA) or remain unclassified/
idiopathic in the absence of any identifiable autoantibodies.
Our study has limitations. The small sample size did not
allow us to conduct formal statistical analyses. We were
surprised by the lack of improvement in DLCO among
subjects whose FVC improved on therapy; one possible and
likely explanation for this is the intrinsic variability of the
DLCO maneuver combined with the small sample size. Like
all data generated from patients evaluated at a specialized
referral center, data from this study are inherently biased,
which detracts from the external validity and potential
generalizability of results. In addition, the lack of a system-
atic decision-making regarding whether to test for anti-tRS
antibodies and how to approach therapy is a pitfall of this
retrospective study. However, the purpose of this study was
not to decipher the best approach to ILD therapy in patients
with anti-PL-7 or anti-PL-12 antibodies; rather, it was con-
ducted in an attempt to achieve three specific goals: First, to
add to the limited literature of non-anti-Jo-1 AS syndrome.
The lack of, up-to-recently, commercially available testing
for non-anti-Jo-1 AS antibodies meant that many patients
with non-anti-Jo-1 AS syndrome were likely given a clinical
summary diagnosis of idiopathic ILD. Second, we wanted to
highlight the chest HRCT findings of ILD associated with the
AS syndrome that include extreme basilar predominance of
findings, including reticular and ground glass opacities and
traction bronchiectasis with or without consolidation, that
hug or ‘‘pancake’’ the diaphragms, and the lower lobe
volume loss, with the major fissures being dragged caudally.
Finally, we wished to emphasize the challenges physicians
face in treating ILD in the AS syndrome.
We send our samples for non-Jo-1 anti-synthetase antibody
testing to the Myositis Testing Laboratory at the Oklahoma
Medical Research Foundation (OMRF). Specimen handling and
mailing instruction are found on their website at http://www.
omrf.org/OMRF/Core/MyositisLab.asp. We are not certain
whether specimens can be sent from overseas to OMRF orwhether there are centers outside the U.S. performing similar
testing that is commercially available.
Despite meeting our goals for this study, many questions
remaindfor example, what is the best immunomodulatory
agent to use for AS syndrome-associated ILD? Does anti-tRS
antibody type inform decision-making with respect to
which therapeutic agent to institute? Which AS syndrome
patients should be treated? For how long? Does the ILD in
patients with AS syndrome ‘‘behave’’ similar to other CTD-
related ILD? Similar to idiopathic disease? We can only hope
to begin to answer some of these questions if we are able to
accurately identify and prospectively study more patients
with this condition.
In conclusion, we have described the clinical character-
istics of nine patients who presented with an ‘‘idiopathic’’
interstitial pneumonia and were ultimately diagnosed with
anti-PL-7 or anti-PL-12 antibody positive AS syndrome. Each
subject was ANA and anti-Jo-1 negative, and each presented
with a HRCT scans suggestive of NSIP with or without over-
lapping organizing pneumonia. Effective cross-specialty
collaboration among pulmonologists and rheumatologists led
to the detection subtle extra-thoracic features of the AS
syndrome. Among patients with ‘‘idiopathic’’ NSIP, consid-
eration should be given to AS syndrome and a full comple-
ment of anti-tRS antibodies should be checked.
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